SERPINA7 and neoplasm: Finally, tumor proliferation was evaluated by Ki-67 IHC and both TBG-siCDK11-treated (P = 0.004) and TBG-siCK2-treated tumors demonstrated reduced proliferation rates (Figure 6D).